This study is currently not recruiting participants.

OPZ003; Phase 1b/2 Multicenter Open-label Study of Oprozomib and Dexamethasone in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma

  • STATUS
    Not Recruiting
Send
Updated on 19 February 2024

Summary

The purpose of this study is deteremine the maximum tolerated dose(MTD) of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide and to evaluate the safety and tolerability of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide.

Description

The purpose of this study is to establish the maximum tolerated dose (MTD) of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide and to evaluate the safety and tolerability of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide.

Details
Condition multiple myeloma
Age 18years - 100years
Clinical Study IdentifierTX4228
Last Modified on19 February 2024

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.